ATE287391T1 - Stickstoff-senf-verbindungen und prodrugs dafür - Google Patents

Stickstoff-senf-verbindungen und prodrugs dafür

Info

Publication number
ATE287391T1
ATE287391T1 AT00918981T AT00918981T ATE287391T1 AT E287391 T1 ATE287391 T1 AT E287391T1 AT 00918981 T AT00918981 T AT 00918981T AT 00918981 T AT00918981 T AT 00918981T AT E287391 T1 ATE287391 T1 AT E287391T1
Authority
AT
Austria
Prior art keywords
compounds
prodrugs
nitrogen mustard
group
independently
Prior art date
Application number
AT00918981T
Other languages
English (en)
Inventor
Caroline Joy Springer
Lawrence Christopher Davies
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Application granted granted Critical
Publication of ATE287391T1 publication Critical patent/ATE287391T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/36Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
AT00918981T 1999-03-31 2000-03-29 Stickstoff-senf-verbindungen und prodrugs dafür ATE287391T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9907414.8A GB9907414D0 (en) 1999-03-31 1999-03-31 Improvements relating to prodrugs
PCT/GB2000/001194 WO2000058271A1 (en) 1999-03-31 2000-03-29 Nitrogen mustard compounds and prodrugs therefor

Publications (1)

Publication Number Publication Date
ATE287391T1 true ATE287391T1 (de) 2005-02-15

Family

ID=10850714

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00918981T ATE287391T1 (de) 1999-03-31 2000-03-29 Stickstoff-senf-verbindungen und prodrugs dafür

Country Status (10)

Country Link
US (1) US6852755B1 (de)
EP (1) EP1165493B1 (de)
JP (1) JP2002540186A (de)
AT (1) ATE287391T1 (de)
AU (1) AU3974600A (de)
CA (1) CA2364622A1 (de)
DE (1) DE60017551T2 (de)
GB (1) GB9907414D0 (de)
NZ (1) NZ513759A (de)
WO (1) WO2000058271A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220319D0 (en) * 2002-09-02 2002-10-09 Cancer Res Campaign Tech Enzyme activated self-immolative nitrogen mustard drugs
EP2077991B1 (de) * 2006-10-03 2014-02-26 Techfields Biochem Co. Ltd Positiv geladene, wasserlösliche prodrugs von losten und verwandten verbindungen mit sehr hohen hautpenetrationsraten

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US5662896A (en) 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
GB8820850D0 (en) 1988-09-05 1988-10-05 Cancer Res Campaign Tech Improvements relating to pro-drugs
EP0845537A1 (de) 1989-08-18 1998-06-03 Chiron Corporation Rekombinante Retroviren, die einen Prodrug exprimieren, zur Behandlung von GVhD
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
GB8920011D0 (en) 1989-09-05 1989-10-18 Mann J New route of synthesis for tertiary butyl esters
EP0572401B2 (de) 1991-02-19 2007-11-07 The Regents of the University of California Viruspartikel mit veraendertem wirtspektrum
EP0615453B1 (de) 1991-11-29 1997-05-14 Chiron Viagene, Inc. Immuntherapeutische vektorkonstrukte gegen krebs
GB9314960D0 (en) 1992-07-23 1993-09-01 Zeneca Ltd Chemical compounds
GB9308957D0 (en) 1993-04-30 1993-06-16 Cancer Res Campaign Tech Novel produgs
WO1995007994A2 (en) 1993-09-15 1995-03-23 Viagene, Inc. Recombinant alphavirus vectors
CA2158936C (en) 1993-11-18 2012-02-21 Jack R. Barber Compositions and methods for utilizing conditionally lethal genes
GB9415167D0 (en) 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
GB9501052D0 (en) 1995-01-19 1995-03-08 Cancer Res Campaign Tech Improvements relating to prodrugs
GB9514993D0 (en) 1995-07-21 1995-09-20 Pharmacia Spa Site specific phenyl nitrogen mustards
GB9601640D0 (en) 1996-01-26 1996-03-27 Cancer Res Campaign Tech Ligand directed enzyme prodrug therapy

Also Published As

Publication number Publication date
US6852755B1 (en) 2005-02-08
JP2002540186A (ja) 2002-11-26
EP1165493A1 (de) 2002-01-02
EP1165493B1 (de) 2005-01-19
AU3974600A (en) 2000-10-16
GB9907414D0 (en) 1999-05-26
CA2364622A1 (en) 2000-10-05
DE60017551D1 (de) 2005-02-24
DE60017551T2 (de) 2006-01-12
NZ513759A (en) 2001-09-28
WO2000058271A1 (en) 2000-10-05

Similar Documents

Publication Publication Date Title
BRPI0415525A (pt) derivados de imidazola e seu uso como agentes farmacêuticos
IS6658A (is) Ný efnasambönd
IS6520A (is) Ný efnasambönd
CY1110332T1 (el) Παραγωγα βενζιμιδαζολης, συνθεσεις που τα περιεχουν, παρασκευη αυτων και χρηση τους
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
AR011116A1 (es) Compuesto derivado de n-hidroxi-beta-sulfonil propionamida y composicion farmaceutica que lo contiene
WO2004018475A3 (en) Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents
EP1819227A4 (de) Pharmazeutische formulierungen von decitabin
PL367682A1 (en) Dolastatin 10 derivatives
SE0302139D0 (sv) Novel compounds
ATE233754T1 (de) Diphenyl-piperidin derivate
TR200101978T2 (tr) 3,3-Biarilpiperidin ve 2,2-biarilmorfolin türevleri.
UY29234A1 (es) Derivados de adamantano, composiciones farmacéuticas que los contienen, procedimientos de preparación de ambos y aplicaciones.
ATE381554T1 (de) Aroylfurane und aroylthiophene, die sich für die behandlung von krebs eignen
WO2004080960A3 (en) Methods and compositions for the enzymatic synthesis of gangliosides
SE0300456D0 (sv) Novel compounds
SE0003476D0 (sv) Compounds
SE0303280D0 (sv) Novel compounds
EA200600992A1 (ru) Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение
SE9902551D0 (sv) Novel compounds
MXPA02012426A (es) Compuestos nuevos.
ATE287391T1 (de) Stickstoff-senf-verbindungen und prodrugs dafür
YU19302A (sh) 4-benzilaminohinolin konjugovan žučnom kiselinom i njegovi heteroanalozi, postupak za njihovu proizvodnju, lekovi koji sadrže ta jedinjenja i njihova primena
SE0302755D0 (sv) Novel compounds
TW200504051A (en) Novel acridine derivatives and their use as medicaments

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties